WIN Metals Ltd (ASX:WIN)

Ligand Pharmaceuticals Cash Flow Statement

Financials in millions AUD. Fiscal year is July - June.

Fiscal Year	TTM	FY 2024	FY 2023	FY 2022	FY 2020	FY 2019
Period Ending	Dec 31, 2024	Jun 30, 2024	Jun 30, 2023	Jun 30, 2022	Jun 30, 2020	Jun 30, 2019
Net Income	-33.74	-2.3	-2.06	-2.04	-0.03	-0.03
Depreciation & Amortization	31.59	0.79	0.39	0.07	-	-
Loss (Gain) From Sale of Assets	-0.03	-0.03	-	-	-	-
Stock-Based Compensation	0.18	0.18	0.35	0.9	-	-
Other Operating Activities	0.5	-6.76	-14.15	-5.92	-	-
Change in Accounts Receivable	0.11	0.11	0.04	-0.12	-	-
Change in Accounts Payable	-2.66	-2.66	0.58	2.03	-	-
Change in Other Net Operating Assets	0.04	0.04	-0.06	0	-	-
Operating Cash Flow	-4	-10.62	-14.92	-5.09	-0.03	-0.03
Capital Expenditures	-0.12	-0.37	-1.15	-0.5	-0.49	-0.7
Sale of Property, Plant & Equipment	0.12	0.12	-	-	-	-
Cash Acquisitions	-1.04	-	-	0.03	-	-
Other Investing Activities	0.03	0.15	0.2	0.03	-	-
Investing Cash Flow	-0.03	-0.1	-0.96	-0.44	-0.49	-0.7
Short-Term Debt Issued	-	-	-	-	0.6	0.82
Long-Term Debt Issued	-	-	0.07	-	-	-
Total Debt Issued	-	-	0.07	0.12	0.6	0.82
Long-Term Debt Repaid	-	-0.17	-0.15	-	-	-
Total Debt Repaid	-0.17	-0.17	-0.15	-0.05	-	-
Net Debt Issued (Repaid)	-0.17	-0.17	-0.08	0.07	0.6	0.82
Issuance of Common Stock	4.88	0.85	12.07	18.78	-	-
Other Financing Activities	-0.38	-0.11	-0.7	-1	-	-
Financing Cash Flow	4.33	0.57	11.29	17.85	0.6	0.82
Net Cash Flow	0.29	-10.15	-4.59	12.33	0.08	0.09
Free Cash Flow	-4.12	-11	-16.08	-5.58	-0.52	-0.74
Free Cash Flow Per Share	-0.01	-0.04	-0.06	-0.03	-0.00	-
Cash Interest Paid	0.01	0.01	0.01	0.01	-	-
Cash Income Tax Paid	-	-1.18	-	-	-	-
Levered Free Cash Flow	9.84	-4.16	-1.29	-	-0.56	-
Unlevered Free Cash Flow	9.85	-4.15	-1.28	-	-0.56	-
Change in Net Working Capital	0.48	3.22	-0.55	-	0.05	-

Updated Mar 12, 2025. Source: S&P Global Market Intelligence. Standard template. Financial Sources.